Navigation Links
Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance
Date:3/17/2011

ceptance of our existing products; our ability to realize the anticipated opportunities from the PGP Acquisition; and the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2010, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law. WARNER CHILCOTT PUBLIC LIMITED COMPANY2011 Full Year Financial Guidance(In millions of U.S. dollars, except per share amounts)Prior Guidance
February 2011 Current Guidance
March 2011Total Revenue (1)$2,700 to $2,800$2,700 to $2,800Gross Margin as a % of Total Revenue (2)88% to 89%88% to 89%Total SG&A Expense (3)$900 to $950$900 to $950Total R&D Expense (4)$150 to $170$150 to $170Total Income Tax Provision (5)10%-11% of EBTA10%-11% of EBTAGAAP Net Income (6)$270 to $296$255 to $281Cash Net Income ("CNI") (7)$883 to $909$922 to $948CNI per share (6) (7)$3.45 to $3.55$3.60 to $3.70(1)

The 2011 guidance assumes (i) that generic equivalents of our DORYX 150 mg, ASACOL 400 mg and ESTRACE CREAM products will not be approved and enter the U.S. market during 2011; (ii) that a generic equivalent of FEMCON FE will be approved and enter the market as early as March 2011; (iii) the expected impact of the loss of exclusivity for ACTONEL in Western European markets and (iv) the growth of our promoted products as compared to the prior year. In addition our 2011 guidance accounts for revenues expected from the launch of ATELVIA and LO LOESTRIN FE in January 2011. The guidance does not ac
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
2. Warner Chilcott Announces 2011 Financial Guidance Conference Call
3. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
9. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
(Date:9/30/2014)... 30, 2014 On September 11, Pharma IQ ... in anticipation of a session that he will lead on ... scheduled for February 17-18, 2015 in London. In the ... asked Dr. Sherley to respond to several questions on the ... to evaluating stem cell toxicity, and future trends in the ...
(Date:9/30/2014)... September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, Pennsylvania, ... and Safety (ACRES), a Massachusetts non-profit charitable ... alliance agreement, setting the stage for multiple collaborative ... clinical research quality and safety through specialized nursing ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... , MONTREAL, Dec. 7 /PRNewswire/ - Enerkem Inc. ... been selected by the U.S. Department of Energy (DOE) to ... of its waste-to-biofuels facility to be located in Pontotoc, Mississippi. ... been selected in the larger demonstration scale project category of ...
... 7 ATS Medical, Inc. (Nasdaq: ATSI ), ... services today announced it has received CE Mark approval ... the European Union, indicating it is compliant with relevant ... The Enable valve is the first surgical aortic valve ...
... ... develop systems biology-driven therapeutics to include small molecules, chemotherapy and RNAi candidates and ... ... announced today that it has acquired Hermes Biosciences, Inc. a private biotechnology company ...
Cached Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
(Date:9/29/2014)... in Behavioral Brain Research provides novel insight ... result of chronic alcohol exposure that can lead to ... and research indicate that individuals with alcohol use disorders ... when people are actively drinking, when they are going ... "Sleep-wake disturbances can last for months, or even years, ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2
... Scientists have new information about the complex genetic ... of cognitive decline and dementia in the elderly. ... January issue of the American Journal of ... to look for genes associated with this devastating ...
... cancer cells for the whereabouts of an important tumor-suppressor, they ... broth instead of muscling its way out to the cells, ... of delinquency puzzled scientists for a long time until ... Medicine felt compelled to genetically grab the protein by the ...
... clinical trial suggests that long-term use of candesartan, a ... the symptoms of genetic heart disease. The related ... on left ventricular hypertrophy and function in non-obstructive hypertrophic ... issue of The Journal of Molecular Diagnostics . ...
Cached Biology News:Scientists make strides toward defining genetic signature of Alzheimer's disease 2Johns Hopkins scientists pull protein's tail to curtail cancer 2
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Feline IL-2, CF...
Recombinant Equine IL-4, CF...
Recombinant Rat Leptin, CF...
Biology Products: